Natural alteration of antibody titers in a patient with immunoglobulin A deficiency after chickenpox over a 10‐year period

Abstract

The infant developed acute myeloid leukemia at the age of 31 months (26 months after she was diagnosed with DNH). 7 It is well known that childhood cancer survivors are at high risk of developing a second neoplasm; particularly in patients at a young age at diagnosis, with escalated doses of alkylating agents, and with the use of anthracyclines or epipodophyllotoxins. 8 Hawkins reported that a cumulative dose of CPA over 4400 mg/m 2 causes acute myeloid leukemia with relative risk of over 2.7. 9 We gave 1575 mg/m 2 of CPA, which is very low compared with cases already reported.Recently bevacizumab, a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor, or sorafenib, a tyrosine kinase inhibiter, are clinically applied to inhibit angiogenesis. Theoretically these agents may not act directly against genomic DNA replication, and could be applied for DNH with an expectation for less secondary cancer.In conclusion, low-dose CPA proved most effective after multimodal treatment against DNH in our case. Further follow up is warranted for secondary malignancies. References

Changes of Antibody Associated with Cell-Mediated Immunity in College Students During Two Years after Rubella Vaccination

“…Kato et al reported that 86% of previously seropositive hospital workers remained seropositive for over 3~5 years [18]. However, previous studies have shown that antibody responses in humans do not reach steady levels until approximately 2~4 years after infection or vaccination [19][20][21]. Therefore, the timing of the present study (2 years after vaccination) may have been too early to detect antibody levels in the steady period.…”